MSLN and neoplasm: To evaluate whether MSLN×CD16A induces CIML NK cell effector activation against MSLN-positive tumor cells in vitro, CIML NK cells were cocultured with various target cells for 6 h and treated with PBS or equal concentrations of the effector-end CD16A-SpyTag, target-end MSLN-SpyCatcher, or MSLN×CD16A.